Plain-English translation of NCT06119490 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether combining a steroid medication (methylprednisolone) with one of two new drugs called JAK inhibitors—either or —can help treat toxic epidermal necrolysis (TEN), a rare and severe skin condition. You would receive either or alongside the steroid to see if this combination works better and is safe for people with this condition.
Toxic epidermal necrolysis is a life-threatening skin reaction that causes the skin to peel and blister, often triggered by medications. Doctors currently use steroids to treat it, but researchers want to see if adding one of these newer medications can improve outcomes and help patients recover more safely.
You would be assigned to receive either the combination or the combination alongside methylprednisolone. You would take these medications daily as prescribed and attend follow-up visits so the research team can monitor how well the treatment works and check for any side effects. The trial will track your skin healing, overall health, and safety throughout your participation.
AI-generated summary from trial data · Sep 11, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Peng Zhang
Enrollment target
~30 participants
Started
July 2023
Primary completion
July 2026
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in November 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Chao Ji
Peng Zhang